The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception
MV Dhodapkar - American journal of hematology, 2023 - Wiley Online Library
Multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined
significance (MGUS) are distinct disorders that likely originate in the setting of chronic …
significance (MGUS) are distinct disorders that likely originate in the setting of chronic …
MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies
M Alcoceba, M García-Álvarez, A Medina… - International Journal of …, 2022 - mdpi.com
The MYD88 gene has a physiological role in the innate immune system. Somatic mutations
in MYD88, including the most common L265P, have been associated with the development …
in MYD88, including the most common L265P, have been associated with the development …
Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma
KM Dhodapkar, AD Cohen, A Kaushal, AL Garfall… - Blood Cancer …, 2022 - AACR
Chimeric antigen-receptor (CAR) T cells lead to high response rates in myeloma, but most
patients experience recurrent disease. We combined several high-dimensional approaches …
patients experience recurrent disease. We combined several high-dimensional approaches …
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough …
MI Azeem, AK Nooka, U Shanmugasundaram… - Blood cancer …, 2023 - AACR
Patients with multiple myeloma (MM) mount suboptimal neutralizing antibodies (nAb)
following 2 doses of SARS-CoV-2 mRNA vaccines. Currently, circulating SARS-CoV-2 …
following 2 doses of SARS-CoV-2 mRNA vaccines. Currently, circulating SARS-CoV-2 …
Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial
Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade lymphoma with no standard
therapy. Nine asymptomatic patients treated with a first-in-human, neoantigen DNA vaccine …
therapy. Nine asymptomatic patients treated with a first-in-human, neoantigen DNA vaccine …
Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis
A Sacco, V Desantis, J Celay, V Giustini… - Blood, The Journal …, 2023 - ashpublications.org
Recent investigations have improved our understanding of the molecular aberrations
supporting Waldenström macroglobulinemia (WM) biology; however, whether the immune …
supporting Waldenström macroglobulinemia (WM) biology; however, whether the immune …
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined …
DF Moreno, M López‐Guerra, S Paz… - British Journal of …, 2023 - Wiley Online Library
Waldenström macroglobulinaemia (WM) is characterized by recurrent somatic mutations in
MYD88 and CXCR4 genes. However, limitations arise when analysing these mutations in …
MYD88 and CXCR4 genes. However, limitations arise when analysing these mutations in …
Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia
H Sun, T Fang, T Wang, Z Yu, L Gong, X Wei… - Journal of Translational …, 2022 - Springer
Background Waldenström macroglobulinemia (WM) is a rare and incurable indolent B-cell
malignancy. The molecular pathogenesis and the role of immunosuppressive …
malignancy. The molecular pathogenesis and the role of immunosuppressive …
Immune-pathogenesis of myeloma
MV Dhodapkar - Hematology/Oncology Clinics, 2024 - hemonc.theclinics.com
Multiple myeloma (MM) is a common hematologic malignancy involving progressive growth
of malignant plasma cells, predominantly in the bone marrow. 1 It is now well established …
of malignant plasma cells, predominantly in the bone marrow. 1 It is now well established …
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity
The role of the bone marrow (BM) microenvironment in regulating the antitumor immune
response in Waldenstrom macroglobulinemia (WM) remains poorly understood. Here we …
response in Waldenstrom macroglobulinemia (WM) remains poorly understood. Here we …